(130 days)
Stimulation of peripheral nerves.
Not Found
The provided document is an FDA 510(k) clearance letter for the Magstim Rapid device. It states that the device is substantially equivalent to legally marketed predicate devices for the indication of "Stimulation of peripheral nerves."
However, this document does not contain any information regarding acceptance criteria, device performance metrics, study designs (e.g., sample sizes, ground truth establishment, expert qualifications, or MRMC studies), or specific results of any performance studies.
Therefore, I cannot fulfill your request for the information outlined in your prompt using only the provided text. The document is an administrative clearance letter, not a technical report detailing performance assessment.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle-like symbol with three curved lines forming its body and head. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the symbol.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
JAN - 7 2000
Reza Jalinous, Ph.D. Technical & Clinical Director Magstim Corporation US 730 Fifth Avenue, 9th Floor New York, New York 10019-4105
Re: K992911
Trade Name: Magstim Rapid (Standard and Super versions) with Dual 70-mm Coil and Circular 90-mm Coil Regulatory Class: II Product Codes: 84 GWF and 84 JXE Dated: December 2, 1999 Received: December 3, 1999
Dear Dr. Jalinous:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: This response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{1}------------------------------------------------
Page 2 - Reza Jalinous, Ph.D.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its Internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Russell Sage
dro James E. Dillard III Acting Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
INDICATIONS FOR USE
510(K) Number (if known): K9929 | l Device Name: Magstim Rapid
Indications for Use:
Stimulation of peripheral nerves.
Concurrence of CDRH, Office of Device Evaluation (ODE)
Lennell/m
General
Prescription Use: (Per 21 CFR 801.109)
OR
Over-The-Counter Use: ________________________________________________________________________________________________________________________________________________________
§ 882.1870 Evoked response electrical stimulator.
(a)
Identification. An evoked response electrical stimulator is a device used to apply an electrical stimulus to a patient by means of skin electrodes for the purpose of measuring the evoked response.(b)
Classification. Class II (performance standards).